3 results match your criteria: "Hospices Civils de Lyon and University de Lyon[Affiliation]"
Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study.
Lancet Diabetes Endocrinol
October 2023
Oncology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health Medical, ASST-Spedali Civili, University of Brescia, Brescia, Italy.
Background: Adjuvant treatment with mitotane is commonly used after resection of adrenocortical carcinoma; however, treatment remains controversial, particularly if risk of recurrence is not high. We aimed to assess the efficacy and safety of adjuvant mitotane compared with surveillance alone following complete tumour resection in patients with adrenocortical carcinoma considered to be at low to intermediate risk of recurrence.
Methods: ADIUVO was a multicentre, open-label, parallel, randomised, phase 3 trial done in 23 centres across seven countries.
Improved Outcome of Infantile Oxalosis Over Time in Europe: Data From the OxalEurope Registry.
Kidney Int Rep
July 2022
Department of Pediatric Nephrology, Hospices Civils de Lyon and University de Lyon, Lyon, France.
Article Synopsis
- Infantile oxalosis, a severe form of primary hyperoxaluria type 1, leads to end-stage kidney disease (ESKD) in infants, with a study analyzing 95 cases from 1980 to 2018 revealing critical patient outcomes.
- Among the findings, the median age for ESKD onset was just 0.4 years, with a significant number of patients (30%) dying by the age of 1.4 years despite advancements in survival rates for those born post-2000.
- Systemic oxalosis was prevalent in almost all patients screened, highlighting the need for ongoing research into the genetic variability observed within families affected by infantile oxalosis.
Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up.
Kidney Int
December 2019
Department of Nephrology, Birmingham Children's Hospital NHS Foundation Trust, Birmingham, UK.
Primary hyperoxaluria type 2 is a rare inherited disorder of glyoxylate metabolism causing nephrocalcinosis, renal stone formation and ultimately kidney failure. Previously, primary hyperoxaluria type 2 was considered to have a more favorable prognosis than primary hyperoxaluria type 1, but earlier reports are limited by low patient numbers and short follow up periods. Here we report on the clinical, genetic, and biochemical findings from the largest cohort of patients with primary hyperoxaluria type 2, obtained by a retrospective record review of genetically confirmed cases in the OxalEurope registry, a dataset containing 101 patients from eleven countries.
View Article and Find Full Text PDF